Mylan Introduces Generic Micardis Tablets - Quick Facts

(RTTNews) - Mylan Inc. (MYL) said it has launched Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, the generic version of Boehringer Ingelheim's Micardis Tablets. It received final approval from the U.S. Food and Drug Administration or FDA for its Abbreviated New Drug Application or ANDA for this product, that is indicated to treat hypertension, to lower blood pressure.

Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, generated U.S. sales of about $259.2 million for the year ending March 31, 2014, according to IMS Health.

According to IMS Health, Mylan currently has 305 ANDAs pending FDA approval representing $107.2 billion in annual brand sales. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $25.0 billion in annual brand sales, for the 12 months ending December 31, 2013, as per IMS Health.